Lacrimal Duct Stent Tubes

Lacrimal Duct Stent Tubes

Global Lacrimal Duct Stent Tubes Market to Reach US$46.5 Million by 2030

The global market for Lacrimal Duct Stent Tubes estimated at US$40.0 Million in the year 2023, is expected to reach US$46.5 Million by 2030, growing at a CAGR of 2.2% over the analysis period 2023-2030. Bicanalicular Tubes, one of the segments analyzed in the report, is expected to record a 2.4% CAGR and reach US$35.0 Million by the end of the analysis period. Growth in the Monocanalicular Tubes segment is estimated at 1.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$10.9 Million While China is Forecast to Grow at 4.5% CAGR

The Lacrimal Duct Stent Tubes market in the U.S. is estimated at US$10.9 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$9.1 Million by the year 2030 trailing a CAGR of 4.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.5% and 1.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.0% CAGR.

Global Lacrimal Duct Stent Tubes Market - Key Trends and Drivers Summarized

Lacrimal duct stent tubes are medical devices used to treat conditions related to the lacrimal system, which is responsible for the drainage of tears from the eye into the nasal cavity. These stent tubes are particularly used in cases where the natural tear ducts are blocked, causing excessive tearing and discomfort, a condition known as dacryocystitis. Lacrimal duct stent tubes help to restore the proper flow of tears by opening up the blocked ducts. The procedure for inserting these tubes, typically a minimally invasive surgery known as dacryocystorhinostomy, involves creating a new route for tears to pass from the lacrimal sac into the nose. The stents are usually made from silicone and are designed to be biocompatible and flexible, which minimizes the risk of irritation and allows them to be in place for extended periods if necessary.

The design and manufacturing of lacrimal duct stent tubes have seen significant advancements over the years. Modern stent tubes are more effective and comfortable for patients, incorporating features that reduce the risk of infection and increase the longevity of the device`s functionality. Recent developments include the use of drug-eluting stents, which slowly release medications to prevent inflammation or infection directly at the site of implantation. Additionally, improvements in the imaging technologies used during insertion procedures, such as endoscopic techniques, have enhanced the precision and safety of the surgery, leading to better outcomes and shorter recovery times for patients. These technological advancements not only improve patient comfort and procedure success rates but also contribute to the overall efficiency of treatments for tear duct obstructions.

The growth in the lacrimal duct stent tubes market is driven by several factors, including increasing prevalence of lacrimal system disorders, technological advancements in stent design and surgery, and a growing preference for minimally invasive surgical procedures. As populations age, the incidence of conditions like dry eye and other tear duct abnormalities increases, creating a higher demand for effective treatment solutions such as stenting. Technological innovations that enhance the safety and efficacy of lacrimal duct surgeries and stent implementations are key to this market’s expansion. Additionally, as consumer awareness of available treatment options grows, more patients are likely to opt for procedures that promise quicker recovery and fewer complications, such as those involving advanced stent tubes. Furthermore, improvements in healthcare infrastructure and increased healthcare spending globally enable greater access to such specialized medical treatments, supporting the growth of the lacrimal duct stent market. Together, these factors are propelling the adoption of lacrimal duct stents as a standard treatment for relevant ophthalmic conditions.

Select Competitors (Total 46 Featured) -

• BVI Medical
• FCI Ophthalmics
• Gunther Weiss Scientific Glassblowing Co., Inc.
• Kaneka Medical America LLC
• Medline Industries, LP.
• Surtex Instruments
• Walsh Medical Devices Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.